Showing results (391-400 of 439) with videos related to

Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Shuangtao Zhao, Hun Ju Lee, et al.
American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
The Lancet. Haematology|June 6, 2024
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trialJillian R Gunther, Jie Xu, Manoop S Bhutani, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Cell Reports. Medicine|August 16, 2023
Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cellsPaolo Strati, Xubin Li, Qing Deng, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Blood|February 3, 2021
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sairah Ahmed, Fateeha Furqan, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Pageof 44